Key Idiopathic Pulmonary Fibrosis Treatment Market Players:
- Boehringer Ingelheim International GmbH
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Bumrungrad International Hospital
- Cedars-Sinai
- Cleveland Clinic
- Bristol-Myers Squibb Company
- Cipla Inc.
- FibroGen, Inc.
- Galapagos NV
- Liminal BioSciences Inc.
- MediciNova, Inc.
- Novartis AG
- United Therapeutics
The companies participating in the idiopathic pulmonary fibrosis treatment market are expanding through R&D investments in new therapies, partnerships to accelerate drug discovery, and acquisitions to enhance their treatment portfolios. Many firms are also focusing on geographic expansion, particularly in emerging markets, to increase accessibility. Regulatory engagement, such as securing orphan drug status, is a key strategy to streamline approvals, while digital patient tools for patient monitoring are becoming integral to improving treatment adherence and personalized care. In September 2024, Boehringer Ingelheim released a statement that its study of nerandomilast, FIBRONEER-IPF, effectively met its primary endpoint, encouraging plans for a new drug request for IPF treatment.
